Do analysts rate ZSQR or DCBO?

Docebo has a consensus price target of $31.23, suggesting a potential upside of 36.74%. Given Docebo's stronger consensus rating and higher possible upside, analysts clearly believe Docebo is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Docebo 0 Sell rating(s) 4 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.81

Does the media favor ZSQR or DCBO?

In the previous week, Docebo had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 3 mentions for Docebo and 2 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.89 beat Docebo's score of 0.78 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Docebo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HKD or ZSQR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AMTD Digital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, HKD or ZSQR?

AMTD Digital has higher revenue and earnings than Coeptis Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AMTD Digital $136.10M 3.90 $54.71M N/A N/A Coeptis Therapeutics N/A N/A -$11.92M -$1.63 N/A

Do analysts recommend ZSQR or MFI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 mF International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ZSQR or MFI?

mF International has higher revenue and earnings than Coeptis Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coeptis Therapeutics N/A N/A -$11.92M -$1.63 N/A mF International $4.35M 109.59 $10.12M N/A N/A

Does the media favor ZSQR or MFI?

In the previous week, mF International had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 3 mentions for mF International and 2 mentions for Coeptis Therapeutics. mF International's average media sentiment score of 1.03 beat Coeptis Therapeutics' score of 0.89 indicating that mF International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive mF International 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MTLS or ZSQR?

Materialise presently has a consensus target price of $10.00, indicating a potential upside of 16.55%. Given Materialise's stronger consensus rating and higher possible upside, analysts clearly believe Materialise is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Materialise 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer MTLS or ZSQR?

In the previous week, Materialise had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for Materialise and 2 mentions for Coeptis Therapeutics. Materialise's average media sentiment score of 1.08 beat Coeptis Therapeutics' score of 0.89 indicating that Materialise is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Materialise 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GLOO or ZSQR?

Gloo currently has a consensus price target of $12.00, indicating a potential upside of 157.51%. Given Gloo's stronger consensus rating and higher probable upside, equities analysts plainly believe Gloo is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gloo 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GLOO or ZSQR more profitable?

Gloo has a net margin of -81.35% compared to Coeptis Therapeutics' net margin of -773.72%. Coeptis Therapeutics' return on equity of -49.45% beat Gloo's return on equity. Company Net Margins Return on Equity Return on Assets Gloo -81.35% -1,637.91% -41.56% Coeptis Therapeutics -773.72% -49.45% -46.88%

Does the media favor GLOO or ZSQR?

In the previous week, Gloo had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for Gloo and 2 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.89 beat Gloo's score of 0.30 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gloo 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Coeptis Therapeutics (ZSQR) Competitors

$4.54 +0.76 (+20.11%)

As of 04:00 PM Eastern

Compare

ZSQR vs. DCBO, HKD, MFI, MTLS, and GLOO

Should you buy Coeptis Therapeutics stock or one of its competitors? Coeptis Therapeutics's main competitors and comparable companies include Docebo (DCBO), AMTD Digital (HKD), mF International (MFI), Materialise (MTLS), and Gloo (GLOO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Coeptis Therapeutics compare to Docebo?

Coeptis Therapeutics (NASDAQ:ZSQR) and Docebo (NASDAQ:DCBO) are both small-cap technology companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Docebo has a consensus price target of $31.23, suggesting a potential upside of 36.74%. Given Docebo's stronger consensus rating and higher possible upside, analysts clearly believe Docebo is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Docebo	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.81

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 53.2% of Docebo shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Docebo had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 3 mentions for Docebo and 2 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.89 beat Docebo's score of 0.78 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Docebo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coeptis Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Docebo has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Docebo has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Docebo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A
Docebo	$242.69M	2.36	$37.51M	$1.14	20.04

Docebo has a net margin of 12.98% compared to Coeptis Therapeutics' net margin of -773.72%. Docebo's return on equity of 120.29% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
Docebo	12.98%	120.29%	16.26%

Summary

Docebo beats Coeptis Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Coeptis Therapeutics compare to AMTD Digital?

AMTD Digital (NYSE:HKD) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

AMTD Digital has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -773.72%. AMTD Digital's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMTD Digital	N/A	N/A	N/A
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

5.8% of AMTD Digital shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AMTD Digital has higher revenue and earnings than Coeptis Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMTD Digital	$136.10M	3.90	$54.71M	N/A	N/A
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A

AMTD Digital has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

In the previous week, Coeptis Therapeutics had 2 more articles in the media than AMTD Digital. MarketBeat recorded 2 mentions for Coeptis Therapeutics and 0 mentions for AMTD Digital. Coeptis Therapeutics' average media sentiment score of 0.89 beat AMTD Digital's score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AMTD Digital	Neutral
Coeptis Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMTD Digital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

AMTD Digital beats Coeptis Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Coeptis Therapeutics compare to mF International?

Coeptis Therapeutics (NASDAQ:ZSQR) and mF International (NASDAQ:MFI) are both small-cap technology companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
mF International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

mF International has higher revenue and earnings than Coeptis Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A
mF International	$4.35M	109.59	$10.12M	N/A	N/A

In the previous week, mF International had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 3 mentions for mF International and 2 mentions for Coeptis Therapeutics. mF International's average media sentiment score of 1.03 beat Coeptis Therapeutics' score of 0.89 indicating that mF International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
mF International	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

13.9% of Coeptis Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

mF International has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -773.72%. mF International's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
mF International	N/A	N/A	N/A

Coeptis Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, mF International has a beta of 7.04, suggesting that its share price is 604% more volatile than the broader market.

Summary

mF International beats Coeptis Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Materialise?

Materialise (NASDAQ:MTLS) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, Materialise had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for Materialise and 2 mentions for Coeptis Therapeutics. Materialise's average media sentiment score of 1.08 beat Coeptis Therapeutics' score of 0.89 indicating that Materialise is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Materialise	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.3% of Materialise shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Materialise presently has a consensus target price of $10.00, indicating a potential upside of 16.55%. Given Materialise's stronger consensus rating and higher possible upside, analysts clearly believe Materialise is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Materialise	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Materialise has a net margin of 4.85% compared to Coeptis Therapeutics' net margin of -773.72%. Materialise's return on equity of 5.20% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Materialise	4.85%	5.20%	3.17%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

Materialise has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Materialise has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Materialise, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Materialise	$302.73M	1.67	$8.73M	$0.27	31.78
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A

Summary

Materialise beats Coeptis Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Gloo?

Gloo (NASDAQ:GLOO) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

In the previous week, Gloo had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for Gloo and 2 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.89 beat Gloo's score of 0.30 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gloo	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gloo has a net margin of -81.35% compared to Coeptis Therapeutics' net margin of -773.72%. Coeptis Therapeutics' return on equity of -49.45% beat Gloo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gloo	-81.35%	-1,637.91%	-41.56%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

13.9% of Coeptis Therapeutics shares are owned by institutional investors. 45.2% of Gloo shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Coeptis Therapeutics has lower revenue, but higher earnings than Gloo. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Gloo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gloo	$94.66M	4.51	-$157.13M	-$7.31	N/A
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A

Gloo currently has a consensus price target of $12.00, indicating a potential upside of 157.51%. Given Gloo's stronger consensus rating and higher probable upside, equities analysts plainly believe Gloo is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gloo	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Gloo beats Coeptis Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Coeptis Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZSQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZSQR vs. The Competition

Export

Metric	Coeptis Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$240.62M	$15.83B	$30.84B	$13.03B
Dividend Yield	N/A	3.43%	2.76%	14.03%
P/E Ratio	-2.79	141.75	78.79	25.61
Price / Sales	N/A	1,285.39	588.69	108.06
Price / Cash	N/A	43.71	47.60	35.00
Price / Book	1.73	8.67	8.02	6.44
Net Income	-$11.92M	$432.50M	$701.71M	$360.47M
7 Day Performance	71.97%	-0.93%	-0.92%	-1.03%
1 Month Performance	17.62%	-3.78%	-2.22%	-3.70%
1 Year Performance	-74.06%	-0.75%	179.17%	3.62%

Coeptis Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZSQR Coeptis Therapeutics	0.4178 of 5 stars	$4.54 +20.1%	N/A	-78.4%	$200.34M	$1.36M	N/A	6	News Coverage
DCBO Docebo	4.3949 of 5 stars	$22.59 -1.6%	$31.23 +38.3%	-18.0%	$571.69M	$242.69M	19.82	966
HKD AMTD Digital	0.3364 of 5 stars	$1.70 -0.9%	N/A	-9.2%	$542.51M	$136.10M	N/A	166
MFI mF International	1.0502 of 5 stars	$9.39 -1.1%	N/A	-73.3%	$465.93M	$4.35M	N/A	N/A	Positive News Gap Up
MTLS Materialise	3.5893 of 5 stars	$7.99 +1.9%	$10.00 +25.2%	+50.0%	$463.09M	$302.73M	29.59	2,556	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZSQR) was last updated on 9/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. DCBO, HKD, MFI, MTLS, and GLOO

How does Coeptis Therapeutics compare to Docebo?

Summary

How does Coeptis Therapeutics compare to AMTD Digital?

Summary

How does Coeptis Therapeutics compare to mF International?

Summary

How does Coeptis Therapeutics compare to Materialise?

Summary

How does Coeptis Therapeutics compare to Gloo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. DCBO, HKD, MFI, MTLS, and GLOO

How does Coeptis Therapeutics compare to Docebo?

Do analysts rate ZSQR or DCBO?

Do insiders & institutionals hold more shares of ZSQR or DCBO?

Does the media favor ZSQR or DCBO?

Which has more risk and volatility, ZSQR or DCBO?

Which has better valuation and earnings, ZSQR or DCBO?

Is ZSQR or DCBO more profitable?

Summary

How does Coeptis Therapeutics compare to AMTD Digital?

Is HKD or ZSQR more profitable?

Do insiders and institutionals have more ownership in HKD or ZSQR?

Which has better earnings and valuation, HKD or ZSQR?

Which has more risk and volatility, HKD or ZSQR?

Does the media prefer HKD or ZSQR?

Do analysts recommend HKD or ZSQR?

Summary

How does Coeptis Therapeutics compare to mF International?

Do analysts recommend ZSQR or MFI?

Which has higher valuation and earnings, ZSQR or MFI?

Does the media favor ZSQR or MFI?

Do institutionals & insiders have more ownership in ZSQR or MFI?

Is ZSQR or MFI more profitable?

Which has more volatility and risk, ZSQR or MFI?

Summary

How does Coeptis Therapeutics compare to Materialise?

Does the media prefer MTLS or ZSQR?

Do insiders & institutionals hold more shares of MTLS or ZSQR?

Do analysts rate MTLS or ZSQR?

Is MTLS or ZSQR more profitable?

Which has more risk and volatility, MTLS or ZSQR?

Which has higher valuation and earnings, MTLS or ZSQR?

Summary

How does Coeptis Therapeutics compare to Gloo?

Does the media favor GLOO or ZSQR?

Is GLOO or ZSQR more profitable?

Do insiders and institutionals believe in GLOO or ZSQR?

Which has preferable earnings & valuation, GLOO or ZSQR?

Do analysts rate GLOO or ZSQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools